CN119074873A - 一种中西医结合治疗心衰合并亚临床甲减的药物 - Google Patents
一种中西医结合治疗心衰合并亚临床甲减的药物 Download PDFInfo
- Publication number
- CN119074873A CN119074873A CN202411224513.0A CN202411224513A CN119074873A CN 119074873 A CN119074873 A CN 119074873A CN 202411224513 A CN202411224513 A CN 202411224513A CN 119074873 A CN119074873 A CN 119074873A
- Authority
- CN
- China
- Prior art keywords
- root
- medicine
- heart failure
- traditional chinese
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 159
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 57
- 208000003532 hypothyroidism Diseases 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title claims description 36
- 238000011282 treatment Methods 0.000 claims abstract description 61
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 28
- 229940023019 aconite Drugs 0.000 claims abstract description 28
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 23
- 241000132012 Atractylodes Species 0.000 claims abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 21
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 21
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 20
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 20
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 20
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 20
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 19
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 19
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 19
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 19
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 19
- 241001127714 Amomum Species 0.000 claims abstract description 15
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 claims abstract description 14
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 9
- 235000006533 astragalus Nutrition 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 235000014347 soups Nutrition 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 3
- 241000675108 Citrus tangerina Species 0.000 claims 3
- 244000018633 Prunus armeniaca Species 0.000 claims 3
- 235000009827 Prunus armeniaca Nutrition 0.000 claims 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims 3
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims 3
- 235000017803 cinnamon Nutrition 0.000 claims 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 2
- 229940010454 licorice Drugs 0.000 claims 2
- 244000141331 Amomum villosum Species 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 57
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 20
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 20
- 238000005728 strengthening Methods 0.000 abstract description 20
- 240000007164 Salvia officinalis Species 0.000 abstract description 18
- 244000144725 Amygdalus communis Species 0.000 abstract description 17
- 235000011437 Amygdalus communis Nutrition 0.000 abstract description 17
- 244000197580 Poria cocos Species 0.000 abstract description 17
- 235000008599 Poria cocos Nutrition 0.000 abstract description 17
- 235000020224 almond Nutrition 0.000 abstract description 17
- 235000005412 red sage Nutrition 0.000 abstract description 17
- 229940107666 astragalus root Drugs 0.000 abstract description 15
- 230000006870 function Effects 0.000 abstract description 15
- 241000213006 Angelica dahurica Species 0.000 abstract description 14
- 230000004217 heart function Effects 0.000 abstract description 14
- 229940126673 western medicines Drugs 0.000 abstract description 14
- 235000013399 edible fruits Nutrition 0.000 abstract description 13
- 241000801118 Lepidium Species 0.000 abstract description 11
- 230000001976 improved effect Effects 0.000 abstract description 10
- 241000222640 Polyporus Species 0.000 abstract description 8
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract description 8
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract description 8
- 229940126678 chinese medicines Drugs 0.000 abstract description 6
- 238000002648 combination therapy Methods 0.000 abstract description 6
- 210000001685 thyroid gland Anatomy 0.000 abstract description 5
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 22
- 208000004880 Polyuria Diseases 0.000 description 18
- 230000035619 diuresis Effects 0.000 description 18
- 241001106477 Paeoniaceae Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 14
- 238000010792 warming Methods 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 10
- 244000080767 Areca catechu Species 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000000582 semen Anatomy 0.000 description 9
- 102400001263 NT-proBNP Human genes 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 8
- 208000031975 Yang Deficiency Diseases 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 241000222684 Grifola Species 0.000 description 5
- 244000171085 Polyporus umbellatus Species 0.000 description 5
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010021033 Hypomenorrhoea Diseases 0.000 description 3
- 241000243684 Lumbricus Species 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 102000011923 Thyrotropin Human genes 0.000 description 3
- 108010061174 Thyrotropin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 241000237636 Pheretima Species 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014987 limb edema Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960000939 metoprolol succinate Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中医技术领域,公开了一种中西医结合治疗心衰合并亚临床甲减的药物,该院内协定方包括:制附子10g、白术15g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20、当归12g、砂仁15g、赤芍15g、杏仁10g、大腹皮15g、车前子30g、猪苓12g、茯苓15g、炒葶苈子15g、泽泻12g、大枣10g。该扶阳固本汤联合西药治疗心衰合并亚临床甲减患者的效果显著,患者在进行一段时间的中西医结合疗法后,临床体征得到明显改善,心脏功能和甲状腺功能显著好转,相对于仅用西药治疗的患者,采用中西医结合疗法的治疗效果更佳。目前暂未发现不良反应,说明该药无明显的毒副作用,安全性高,且价格适中,值得在临床推广使用。
Description
技术领域
本发明属于但不限于中医技术领域,尤其涉及一种中西医结合治疗心衰合并亚临床甲减的药物。
背景技术
心力衰竭是以劳力性呼吸困难、运动耐量降低、水肿、体循环或者肺循环淤血等症状为主要表现的临床疾病。患心力衰竭病程较长的患者很容易出现其他并发症,心衰合并亚临床甲减便是一临床常见的合病。亚临床甲状腺功能减退症是一种内分泌系统疾病,这种疾病的实验室检查结果仅显示为TSH水平轻度升高而血清甲状腺激素(FT3,FT4)水平正常。
(1)研究显示,心肌细胞对甲状腺激素有着高度敏感性,甲状腺激素可以影响心脏输出量和动脉粥样硬化的发病率。
(2)还有研究表明,甲减有促进心力衰竭进展的趋势,甲状腺激素药物可以影响心衰患者的预后。
现有的治疗心衰合并亚临床甲减的药物存在以下几个关键问题:
1)稳定性不足:现有药物在体内环境中容易降解,导致疗效不稳定。
2)疗效有限:由于药物组分不够全面,治疗效果往往不理想,特别是在补气活血、利水消肿方面的效果欠佳。
3)副作用较大:某些药物可能会引起较大的副作用,影响患者的依从性。
4)靶向性差:传统药物缺乏针对性,难以有效地靶向治疗心衰合并亚临床甲减的症状。
5)不良反应:有些药物在长期使用过程中可能会引起较多的不良反应。
发明内容
针对现有技术存在的问题,本发明提供了一种中西医结合治疗心衰合并亚临床甲减的药物。
本发明是这样实现的,一种中西医结合治疗心衰合并亚临床甲减的药物,该院内协定方包括:
制附子8-10g、白术10-15g、炙甘草8-10g、地龙10-15g、红参3-6g、黄芪25-30g、桂枝8-10g、丹参15-20g、当归10-12g、砂仁10-15g、赤芍10-15g、杏仁8-10g、大腹皮10-15g、车前子25-30g、猪苓8-12g、茯苓10-15g、炒葶苈子10-15g、泽泻8-12g、大枣8-10g。
进一步,该院内协定方包括:
制附子10g、白术15g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20、当归12g、砂仁15g、赤芍15g、杏仁10g、大腹皮15g、车前子30g、猪苓12g、茯苓15g、炒葶苈子15g、泽泻12g、大枣10g。
本发明另一目的在于提供一种实施所述的中西医结合治疗心衰合并亚临床甲减的药物的制备方法,包括以下步骤:
步骤1,将制附子、白术、炙甘草、地龙、红参、黄芪、桂枝、丹参、当归、砂仁、赤芍、杏仁、大腹皮、车前子、猪苓、茯苓、炒葶苈子、泽泻和大枣分别清洗干净,晾干后切碎或研磨成粗粉状;
步骤2,将上述药材粗粉按配方比例混合均匀后,加入适量清水进行浸泡,浸泡时间为30-60分钟;
步骤3,将浸泡后的药材进行煎煮,煎煮时间为2次,每次30分钟,每次加水量为药材总重量的8-10倍;
步骤4,将两次煎煮液合并,过滤去渣,得到药液,将药液浓缩至适量,制成药汤或药膏;
步骤5,将浓缩后的药液通过喷雾干燥或真空干燥的方法制备成颗粒或粉末剂型,然后根据需求制成冲剂、胶囊或片剂,便于服用和储存。
本发明另一目的在于提供一种基于所述中西医结合治疗心衰合并亚临床甲减的院内协定方的服用方法,该方法包括:
上十九味,水煎服,每剂400ml,每日一剂,每日早晚分次服用200ml;30剂为一个疗程。
结合上述的技术方案和解决的技术问题,本发明所要保护的技术方案所具备的优点及积极效果为:
第一、本发明中以制附子为君药,用其辛甘性热之性以温肾助阳,兼暖脾土,以桂枝为臣,共奏温补心肾、温阳行水之功,红参、黄芪合桂枝、附子以益气健脾,温肾固本。葶苈子、大枣为泻水而不伤脾,但使用时要注意脾胃虚弱的患者应慎用此药组避免泻下过猛而伤及脾胃。白术、猪苓、茯苓、泽泻、车前子诸药相伍,通利小便而祛除湿邪,大腹皮、杏仁,加强助阳化气、利水渗湿,泻肺平喘之功。丹参、赤芍、当归活血养血、化瘀利水,地龙活血通脉,砂仁化湿理气和中。合炙甘草为佐药,制约附子峻烈之性,消除其毒性,补脾益气、镇咳平喘,兼调和诸药。
实验数据表明,该扶阳固本汤联合西药治疗心衰合并亚临床甲减患者的效果显著,患者在进行一段时间的中西医结合疗法后,临床体征得到明显改善,心脏功能和甲状腺功能显著好转,相对于仅用西药治疗的患者,采用中西医结合疗法的治疗效果更佳。目前暂未发现不良反应,说明该药无明显的毒副作用,安全性高,且价格适中,值得在临床推广使用。
第二,本发明提供了一种中西医结合治疗心衰合并亚临床甲减的药物,通过以下技术方案解决上述技术问题:
1)药物组成:制附子10g、白术15g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20g、当归12g、砂仁15g、赤芍15g、杏仁10g、大腹皮15g、车前子30g、猪苓12g、茯苓15g、炒葶苈子15g、泽泻12g、大枣10g。
2)药材配伍:通过精确的药材配伍,综合中药的温阳、补气、活血、利水等功效,形成有效的治疗体系。
3)配伍比例:根据不同病情和体质,调整药材的配伍比例,以达到最佳的治疗效果。
4)综合作用:利用中西医结合的治疗思路,既发挥中药的整体调理作用,又结合西药的精准治疗,确保疗效。
5)个性化调整:根据患者的具体病情和体质,进行个性化调整,增强治疗的靶向性和有效性。
通过上述技术方案,本发明取得了显著的技术进步:
1)提高稳定性:通过采用制附子、白术等药材,有效增强了药物在体内的稳定性,确保疗效持久。
2)增强疗效:通过合理配伍和个性化调整,本发明显著提高了补气活血、利水消肿的效果,对心衰合并亚临床甲减有较好的治疗作用。
3)减少副作用:通过科学配伍和药材筛选,减少了药物的副作用,提高了患者的依从性。
4)靶向治疗:利用中西医结合的治疗方案,增强了药物的靶向性,使得治疗更加精准有效。
5)降低不良反应:通过个性化调整和综合作用,显著降低了药物的长期不良反应,确保患者的安全性和疗效。
综上所述,本发明通过解决现有技术中的稳定性、疗效、副作用、靶向性和不良反应问题,显著提升了治疗心衰合并亚临床甲减的药物水平,具有更广泛的应用前景和更高的实用价值。
附图说明
图1是本发明实施例提供的一种中西医结合治疗心衰合并亚临床甲减的药物的制备方法流程图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
本发明旨在于通过中西医结合的方法探讨治疗心衰合并亚临床甲减的有效疗法,有着切实的社会意义。
真武汤为治疗阳虚证(心肾阳虚证、阳虚水泛证)的要方。心阳、肾阳虚衰则水湿运化困难,寒水内停,从而导致病人咳喘,小便不利,心悸不安,肢体浮肿等症状,利用真武汤温补心肾,温阳利水之效治疗上述病症。笔者在多年的临床工作中总结经验,并结合经典和相关文献,以温肾固本、扶阳利水为治则,在真武汤的基础上进行加减研制出该扶阳固本汤:制附子10g、白术15g、猪苓12g、茯苓15g、车前子30g、泽泻12g、炒葶苈子15g砂仁15g、大腹皮15g、杏仁10g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20、当归12g、赤芍158、大枣10g。
本方中以制附子为君药,用其辛甘性热之性以温肾助阳,兼暖脾土,以桂枝为臣,共奏温补心肾、温阳行水之功,红参、黄芪合桂枝、附子以益气健脾,温肾固本。葶苈子、大枣为泻水而不伤脾,但使用时要注意脾胃虚弱的患者应慎用此药组避免泻下过猛而伤及脾胃。白术、猪苓、茯苓、泽泻、车前子诸药相伍,通利小便而祛除湿邪,大腹皮、杏仁,加强助阳化气、利水渗湿,泻肺平喘之功。丹参、赤芍、当归活血养血、化瘀利水,地龙活血通脉,砂仁化湿理气和中。合炙甘草为佐药,制约附子峻烈之性,消除其毒性,补脾益气、镇咳平喘,兼调和诸药。
实验数据表明,该扶阳固本汤联合西药治疗心衰合并亚临床甲减患者的效果显著,患者在进行一段时间的中西医结合疗法后,临床体征得到明显改善,心脏功能和甲状腺功能显著好转,相对于仅用西药治疗的患者,采用中西医结合疗法的治疗效果更佳。目前暂未发现不良反应,说明该药无明显的毒副作用,安全性高,且价格适中,值得在临床推广使用。
以下是对该协定方各成分及其可能的药理作用的分析:
1)制附子:具有温阳散寒、回阳救逆的作用。在心力衰竭的治疗中,附子可增强心肌收缩力,改善心功能。
2)白术:健脾益气,燥湿利水。对于心衰合并水肿的患者,白术有助于消除体内多余水分,减轻心脏负担。
3)炙甘草:补中益气,调和诸药。炙甘草中的甘草酸等成分具有抗炎、抗氧化、抗心律失常等多种药理作用。
4)地龙:清热息风,通络利尿。地龙含有多种活性成分,如蚓激酶等,具有抗凝、溶栓、降压等作用,对心血管疾病有益。
5)红参:大补元气,复脉固脱。红参中的人参皂苷等成分具有增强心肌收缩力、扩张冠状动脉、改善心肌缺血等作用。
6)黄芪:补气升阳,利水消肿。黄芪是常用的补气药,对心衰患者的心功能改善和水肿消退有积极作用。
7)桂枝:温通经脉,助阳化气。桂枝中的桂皮醛等成分具有扩张血管、增加冠脉血流量等作用,有助于改善心脏供血。
8)丹参、当归、赤芍:这三味药均为活血化瘀药,能够改善微循环,减轻心肌缺血缺氧状态,对心衰患者有益。
9)砂仁:化湿开胃,温脾止泻。砂仁中的挥发油等成分具有促进胃肠蠕动、改善消化功能的作用,有助于心衰患者的营养吸收。
10)杏仁、大腹皮、车前子、猪苓、茯苓、炒葶苈子、泽泻:这些药物均具有利水消肿的作用,有助于心衰患者体内多余水分的排出,减轻心脏负担。
11)大枣:补中益气,养血安神。大枣中的多种营养成分有助于增强患者体质,提高抗病能力。
综合分析,该协定方通过温阳益气、活血化瘀、利水消肿等多种途径,针对心衰合并亚临床甲减的病理生理特点进行治疗。其中,附子、红参、黄芪等药物的强心作用,地龙、丹参等药物的活血化瘀作用,以及多种利水消肿药物的联合应用,共同构成了该协定方的治疗特色。
然而,需要注意的是,中药的药理作用复杂多样,不同药物之间可能存在相互作用。因此,在实际应用中,应根据患者的具体病情和体质特点进行个性化调整,以确保治疗效果和安全性。同时,中西医结合治疗应充分发挥中西医各自的优势,形成互补效应,以达到最佳的治疗效果。
本发明实施例提供一种中西医结合治疗心衰合并亚临床甲减的药物,该院内协定方包括:
制附子10g、白术15g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20、当归12g、砂仁15g、赤芍15g、杏仁10g、大腹皮15g、车前子30g、猪苓12g、茯苓15g、炒葶苈子15g、泽泻12g、大枣10g。
区间配方:制附子8-10g、白术10-15g、炙甘草8-10g、地龙10-15g、红参3-6g、黄芪25-30g、桂枝8-10g、丹参15-20g、当归10-12g、砂仁10-15g、赤芍10-15g、杏仁8-10g、大腹皮10-15g、车前子25-30g、猪苓8-12g、茯苓10-15g、炒葶苈子10-15g、泽泻8-12g、大枣8-10g。
如图1所示,本发明实施例提供一种实施所述的中西医结合治疗心衰合并亚临床甲减的药物的制备方法,包括以下步骤:
S101,将制附子、白术、炙甘草、地龙、红参、黄芪、桂枝、丹参、当归、砂仁、赤芍、杏仁、大腹皮、车前子、猪苓、茯苓、炒葶苈子、泽泻和大枣分别清洗干净,晾干后切碎或研磨成粗粉状;
S102,将上述药材粗粉按配方比例混合均匀后,加入适量清水进行浸泡,浸泡时间为30-60分钟;
S103,将浸泡后的药材进行煎煮,煎煮时间为2次,每次30分钟,每次加水量为药材总重量的8-10倍;
S104,将两次煎煮液合并,过滤去渣,得到药液,将药液浓缩至适量,制成药汤或药膏;
S105,将浓缩后的药液通过喷雾干燥或真空干燥的方法制备成颗粒或粉末剂型,然后根据需求制成冲剂、胶囊或片剂,便于服用和储存。
本发明实施例提供一种基于所述中西医结合治疗心衰合并亚临床甲减的院内协定方的服用方法,该方法包括:
上十九味,水煎服,每剂400ml,每日一剂,每日早晚分次服用200ml;30剂为一个疗程。
一、为了证明本发明的技术方案的创造性和技术价值,该部分是对权利要求技术方案进行具体产品上或相关技术上的应用的应用实施例。
实施例1
药物组成:制附子10g、白术15g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20g、当归12g、砂仁15g、赤芍15g、杏仁10g、大腹皮15g、车前子30g、猪苓12g、茯苓15g、炒葶苈子15g、泽泻12g、大枣10g。本方通过综合各药材的特性,达到了补气、活血、利水、温阳的效果。
实施例2
药物组成:制附子8g、白术20g、炙甘草8g、地龙18g、红参5g、黄芪25g、桂枝12g、丹参22g、当归14g、砂仁12g、赤芍18g、杏仁8g、大腹皮18g、车前子28g、猪苓14g、茯苓12g、炒葶苈子18g、泽泻14g、大枣12g。此方通过调整各药材的用量,进一步增强了补气和活血的作用,同时增加了清热利湿的效果。
实施例3
药物组成:制附子12g、白术12g、炙甘草12g、地龙12g、红参8g、黄芪28g、桂枝8g、丹参18g、当归10g、砂仁10g、赤芍12g、杏仁12g、大腹皮12g、车前子32g、猪苓10g、茯苓18g、炒葶苈子12g、泽泻10g、大枣8g。该方在提升补气温阳的同时,进一步注重利水消肿的作用,适合气虚水肿患者。
实施例4
药物组成:制附子15g、白术18g、炙甘草15g、地龙10g、红参10g、黄芪35g、桂枝15g、丹参25g、当归15g、砂仁20g、赤芍20g、杏仁15g、大腹皮20g、车前子35g、猪苓15g、茯苓20g、炒葶苈子20g、泽泻15g、大枣15g。本方剂通过增加附子、黄芪和桂枝的用量,大大增强了温阳补气的效果,适用于阳虚严重的患者。
实施例5
药物组成:制附子7g、白术10g、炙甘草7g、地龙9g、红参4g、黄芪20g、桂枝9g、丹参15g、当归8g、砂仁9g、赤芍10g、杏仁7g、大腹皮10g、车前子25g、猪苓9g、茯苓10g、炒葶苈子10g、泽泻9g、大枣7g。此方剂在调整剂量的基础上,主要强化了利水消肿的效果,适合水肿较为明显的患者。
实施例6
药物组成:制附子9g、白术13g、炙甘草9g、地龙14g、红参7g、黄芪27g、桂枝13g、丹参23g、当归13g、砂仁13g、赤芍13g、杏仁9g、大腹皮13g、车前子29g、猪苓11g、茯苓13g、炒葶苈子13g、泽泻11g、大枣9g。本方在保证基础配伍的前提下,增加了黄芪、丹参和当归的用量,进一步提升了补气活血的功效。
二、本发明实施例获取的技术效果的相关的证据。
选取42例于2022年1月至2024年3月在岷县中医院心内科住院的心力衰竭(NYHA心功能II-IV级)合并亚临床甲减的患者,随机分为研究组和对照组,对照组(n=21)患者接受常规西药治疗,研究组(n=21)进行中西医结合治疗(即在接受对照组西药治疗的基础上加服笔者自拟的扶阳固本汤)。对比两组治疗前后的临床疗效,记录心衰Lee氏积分、LVEF分数和TSH水平的变化并进行分析对比。
1.参与研究的42例患者皆为岷县中医院在2022年1月到2024年3月期间接诊的心衰合并亚临床甲减患者,随机分成两组:对照组(n=21,男/女为9/12,年龄范围为43~76岁,平均年龄65±6.3岁);研究组(n=21,男/女为8/13,年龄范围为48~77岁,平均年龄67±7.4岁)。
2.诊断标准
心衰诊断标准
西医诊断:①患者出现呼吸困难(每逢劳累或夜间加重)、运动耐力下降、下肢水肿等症状;②心脏超声证实患者存在心脏器质性改变;③左心室射血分数≤49%。
中医诊断:符合中医心衰病范畴,辨证属阳虚的患者(心肾阳虚证、阳虚水泛证):时发心悸,喘息不得卧,尿少肢肿,神疲乏力,畏寒肢冷,腹胀,便溏,口唇发绀,舌淡胖有齿痕,或有瘀点、瘀斑,脉沉细或结、代、促。
3.亚临床甲减诊断标准
经文献查阅,祖国医学中没有关于亚临床甲状腺功能减退症的相关记载,本研究中亚临床甲减患者的诊断以西医诊断标准为准:①患者自觉体力下降、怕冷喜暖、反应迟缓;②实验室检查,患者FT3、FT4水平正常,TSH水平升高。
4.纳入与排除标准
1)纳入标准:年龄符合上述中西医诊断标准,NYHA心功能分级II-Ⅳ级,血清促甲状腺激素水平略高于正常范围上限,而血清甲状腺激素(FT3、FT4)水平处于正常范围,患者无或仅有轻微临床甲减症状的状态,对本次试验知情并签署知情同意书。
2)排除标准:合并其他系统严重疾病;肾功能衰竭、心包炎、重度瓣膜狭窄、系统性红斑狼疮等其他原因引起心脏功能不全,呼吸系统恶性肿瘤,患有精神病,依从性差不能配合;资料不完整。
纳入标准:①患者的实验室检查和影像学检查均符合心力衰竭[10-11]和亚临床甲状腺功能减退症[12-13]的诊断标准;②患者近期未接受其他治疗。
排除标准:①近半年内发生过重大心血管疾病者;②存在沟通障碍者;③对本研究中相关药物存在过敏现象者;④近3个月内服用过能影响甲状腺功能的药物的患者。
5.治疗方法
常规西医组主要给予利尿剂(醛固酮受体拮抗剂、噻嗪类或者袢利尿剂)、β受体阻滞剂(琥珀酸美托洛尔缓释片或比索洛尔片)、ACEI或ARB、钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂(达格列净)。中药联合西药组除了以上常规西药方案外,给予患者我院院内协定方扶阳固本汤口服,坚持口服14天至28天。患者入院时均评中医症候积分、查NT-proBNP、心脏超声、甲功三项,记录EF值。治疗七天后复查以上指标,以观察动态演变。出院后一周、一月进行随访;半年及一年随访,统计再次入院情况。
研究组接受与对照组相同的药物治疗,另外每日服用一剂扶阳固本汤。处方:制附子10g、白术15g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20、当归12g、砂仁15g、赤芍15g、杏仁10g、大腹皮15g、车前子30g、猪苓12g、茯苓15g、炒葶苈子15g、泽泻12g、大枣10g。上十九味,水煎服,每剂400ml,每日一剂,每日早晚分次服用200ml。30剂为一个疗程。为保证汤药浓度和疗效,该治疗中所用汤剂均交由岷县中医院药剂室统一煎制。
6.观察指标
据《中药新药临床研究指导原则》2002版制定本研究的中医症候积分评分细则,对比两组患者治疗前后的中医症候积分以判定临床疗效。若治疗后的中医证候积分为0或者较治疗前减少超过70%,则判定为显效;若治疗后的中医证候积分较前较少30%至70%,则判定为有效;若治疗后的中医症候积分较治疗前减少不超过30%或者比治疗前分数更高,则判定为无效。
心衰Lee氏积分
据心衰疗效治疗Lee氏积分表对每位患者的心脏功能进行打分,记录每位患者治疗前后的Lee氏积分并进行统计学分析。
左心室射血分数
LVEF分数是通过心脏超声检查得到的,是诊断患者心力衰竭和判断心力衰竭程度的重要指标,记录患者治疗前后的EF值以了解患者的心衰程度,并进行统计学分析。
血清促甲状腺激素指标
于患者治疗前后各抽取5ml肘静脉血来测定患者治疗前后的TSH水平,以评估患者的亚临床甲减症状的改善情况。
7.统计学方法
以SPSS26.0软件进行数据的统计与分析,以均数±标准差(x±s)来表示计量资料,以(%)表示计数资料,以t、χ2检验进行数据的比较,P<0.05则数据差异有统计学意义。
8.结果
临床疗效比较
统计治疗后两组的治疗有效率:总有效率=(有效人数+显效人数)*100%/总例数,经治疗后对照组总有效率76.19%,研究组总有效率92.86%,研究组的治疗相对于对照组来说更有效(P<0.05)。见表1。
表1两组患者临床疗效对比[n(%)]
心衰Lee氏积分比较
接受治疗后的Lee氏积分:对照组的为13.11±2.75,研究组的为10.95±2.86低于对照组。见表2。
表2两组治疗前后的Lee氏积分比较(x±s)
LVEF分数比较
记录患者治疗前后的LVEF分数并分析。治疗后,对照组的LVEF分数为52.49±8.46(%),研究组的LVEF分数为56.84±9.24(%),见表3。
表3LVEF分数比较(%)
甲状腺功能比较
抽取患者静脉血测定两组患者接受治疗前后的TSH水平,对照组经过治疗后的TSH值为6.23±1.28,研究组的TSH为5.64±1.37,见表4。
表4TSH指标比较(μIU/mL)
不良反应
42例患者接受治疗期间均未出现不良并发症。
经治疗后,对照组的治疗有效率为76.19%,明显低于研究组的92.86%(P<0.05);两组的心衰Lee氏积分均下降,对照组的Lee氏积分为13.11±2.75,研究组的Lee氏积分为10.95±2.86,研究组的Lee氏积分明显低于对照组(P<0.05);两组的左心室射血分数皆有不同程度的提升,对照组的LVEF分数为52.49±8.46(%),研究组的LVEF分数为56.84±9.24(%),研究组的LVEF分数明显优于对照组(P<0.05);对照组经过治疗后的TSH值为6.23±1.28,明显高于研究组的5.64±1.37(P<0.05)。
病例如下:
病人1
入院时及治疗第7天、第14天进行中医症候评分、NT-proBNp、EF值(射血分数)、甲功三项、Lee氏心衰计分,治疗1月随访,再次进行中医症候积分和心功能评估。
病人2
入院时及治疗第7天、第14天进行中医症候评分、NT-proBNp、EF值(射血分数)、甲功三项、Lee氏心衰计分,治疗1月随访,再次进行中医症候积分和心功能评估。
病人3
入院时及治疗第7天、第14天进行中医症候评分、NT-proBNp、EF值(射血分数)、甲功三项、Lee氏心衰计分,治疗1月随访,再次进行中医症候积分和心功能评估。
病人4
入院时及治疗第7天、第14天进行中医症候评分、NT-proBNp、EF值(射血分数)、甲功三项、Lee氏心衰计分,治疗1月随访,再次进行中医症候积分和心功能评估。
病人5
入院时及治疗第7天、第14天进行中医症候评分、NT-proBNp、EF值(射血分数)、甲功三项、Lee氏心衰计分,治疗1月随访,再次进行中医症候积分和心功能评估。
病人6
入院时及治疗第7天、第14天进行中医症候评分、NT-proBNp、EF值(射血分数)、甲功三项、Lee氏心衰计分,治疗1月随访,再次进行中医症候积分和心功能评估。
病人7
入院时及治疗第7天、第14天进行中医症候评分、NT-proBNp、EF值(射血分数)、甲功三项、Lee氏心衰计分,治疗1月随访,再次进行中医症候积分和心功能评估。
此外,该方剂也可通过用不同的方法制成颗粒剂的形式,提高对红参、丹参等贵重药材的使用率,改善口感,方便携带及用药。具体如下:
1.煎煮法:将上述中药切成片状或者打成粉末状,然后放进合适容器中,加水覆盖药材,浸泡一段时间后再用火进行煎煮,再将分离出来的药液,离心分离或者过滤,最后取得剩下的药膏,分成合适的分量分装,使用时温开水冲服即可。
2.浸渍法:先将药材粉碎,切成片状,然后放在有盖子的瓶子中,然后加入一定的溶剂密封起来。等到三五天后,一般药效会充分的浸出,然后过滤沉淀出药膏;服用方法同上。
3.干燥法:干燥法是将中药中提取出来的成分在做成颗粒状之前最好可以得到粉末状,再将提取出来的中药利用薄膜浓缩技术,反渗透技术和喷雾干燥等干燥技术去除水份。服用方式同上。
也可在不与方中诸药产生相反、相畏的情况下,在该方剂中添加饴糖或蜂蜜等将该方剂制成蜜丸,分以合适的剂量,方便储存,改善方剂的口感,同时提高药物的稳定性,进一步提高患者服药的服从性。
另外,在患者服药的过程中定期随访,嘱患者定期至医院复诊,方便根据患者的反应及用药效果随时加减药物,以起到更好的疗效,提高治疗的针对性及有效性。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,都应涵盖在本发明的保护范围之内。
Claims (4)
1.一种中西医结合治疗心衰合并亚临床甲减的药物,其特征在于,按照质量分来计,包括:
制附子8-10g、白术10-15g、炙甘草8-10g、地龙10-15g、红参3-6g、黄芪25-30g、桂枝8-10g、丹参15-20g、当归10-12g、砂仁10-15g、赤芍10-15g、杏仁8-10g、大腹皮10-15g、车前子25-30g、猪苓8-12g、茯苓10-15g、炒葶苈子10-15g、泽泻8-12g、大枣8-10g。
2.如权利要求1所述的中西医结合治疗心衰合并亚临床甲减的药物,其特征在于,该院内协定方包括:
制附子10g、白术15g、炙甘草10g、地龙15g、红参6g、黄芪30g、桂枝10g、丹参20、当归12g、砂仁15g、赤芍15g、杏仁10g、大腹皮15g、车前子30g、猪苓12g、茯苓15g、炒葶苈子15g、泽泻12g、大枣10g。
3.一种实施如权利要求2所述的中西医结合治疗心衰合并亚临床甲减的药物的制备方法,其特征在于,所述方法包括以下步骤:
步骤1,将制附子、白术、炙甘草、地龙、红参、黄芪、桂枝、丹参、当归、砂仁、赤芍、杏仁、大腹皮、车前子、猪苓、茯苓、炒葶苈子、泽泻和大枣分别清洗干净,晾干后切碎或研磨成粗粉状;
步骤2,将上述药材粗粉按配方比例混合均匀后,加入适量清水进行浸泡,浸泡时间为30-60分钟;
步骤3,将浸泡后的药材进行煎煮,煎煮时间为2次,每次30分钟,每次加水量为药材总重量的8-10倍;
步骤4,将两次煎煮液合并,过滤去渣,得到药液,将药液浓缩至适量,制成药汤或药膏;
步骤5,将浓缩后的药液通过喷雾干燥或真空干燥的方法制备成颗粒或粉末剂型,然后根据需求制成冲剂、胶囊或片剂,便于服用和储存。
4.一种基于如权利要求3所述中西医结合治疗心衰合并亚临床甲减的院内协定方的服用方法,其特征在于,该方法包括:
上十九味,水煎服,每剂400ml,每日一剂,每日早晚分次服用200ml;30剂为一个疗程。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411224513.0A CN119074873A (zh) | 2024-09-03 | 2024-09-03 | 一种中西医结合治疗心衰合并亚临床甲减的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411224513.0A CN119074873A (zh) | 2024-09-03 | 2024-09-03 | 一种中西医结合治疗心衰合并亚临床甲减的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119074873A true CN119074873A (zh) | 2024-12-06 |
Family
ID=93662000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411224513.0A Pending CN119074873A (zh) | 2024-09-03 | 2024-09-03 | 一种中西医结合治疗心衰合并亚临床甲减的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119074873A (zh) |
-
2024
- 2024-09-03 CN CN202411224513.0A patent/CN119074873A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104491415A (zh) | 一种治疗慢性阻塞性肺疾病稳定期的药物及其制备方法 | |
| CN102698207A (zh) | 一种治疗肝病的中药组合物及其制备方法 | |
| CN102988851B (zh) | 一种治疗咳血的中药组合物及制备方法 | |
| CN1046421C (zh) | 治疗肺结核的药物 | |
| CN117599125B (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
| CN108392620B (zh) | 一种治疗皮炎的联合用产品及其用途 | |
| CN105497811A (zh) | 一种治疗肝硬化的中药组合物及其制备工艺 | |
| CN119074873A (zh) | 一种中西医结合治疗心衰合并亚临床甲减的药物 | |
| CN108635457A (zh) | 一种治疗便秘的中药组合物及其制备方法与应用 | |
| CN102805795B (zh) | 一种治疗急性胸胁部软组织损伤的中药组合物及其应用 | |
| CN119792422B (zh) | 一种中药组合物在制备治疗男性性功能及抗疲劳药物的应用 | |
| CN114732889B (zh) | 一种治疗支气管哮喘急性发作期痰浊阻肺证的中药组合物、中药口服制剂 | |
| CN105169187B (zh) | 一种组合物及其应用,其制备方法以及含有该组合物的药物、食品 | |
| CN104306847A (zh) | 一种六味补气胶囊及其制备工艺 | |
| CN110433271A (zh) | 一种治疗功能性消化不良的药物组合物及其制备方法和用途 | |
| CN117045764B (zh) | 一种用于治疗ii型糖尿病的中药组合物及其制备方法 | |
| CN101829213B (zh) | 治疗哮喘的药物组合物及其制备方法 | |
| CN101167915B (zh) | 治疗慢性浅表性胃炎的中药组合物及其制备方法 | |
| CN101204520A (zh) | 一种防治亚健康疲劳的药物组合物及其制备方法 | |
| CN1730093A (zh) | 一种治疗癌症的中药制剂及其应用 | |
| CN101879259B (zh) | 一种治疗肺心病的中药 | |
| CN118767070A (zh) | 一种用于补肾解毒的中药组合物、其浓缩丸的制备方法及用途 | |
| CN121371044A (zh) | 一种治疗社区获得性肺炎恢复期的外用中药组合物及其应用 | |
| CN105343750A (zh) | 一种治疗脾虚胃弱型慢性胃炎的中药组合物及其制备方法 | |
| CN119925512A (zh) | 用于气阴两虚型失眠的中药组合物及其加工方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |